Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Fig. 2

Kaplan–Meier curves of overall survival (left column) and disease free-survival (right column) for pCR (a and b), for treatment with or without zoledronic acid (c and d), and IGF-1R expression before neoadjuvant chemotherapy (e and f). Note: P-values are given for the univariate analyses of the Cox regression analyses. Bold values indicate that P < 0.05. Abbreviations: IGF-1, insulin-like growth factor 1; DFS, disease-free survival; OS, overall survival, pCR, pathological complete response

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us